Cargando…

Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial

OBJECTIVE: To compare the analgesic efficacy and safety of acupuncture and lornoxicam in acute renal colic (ARC). DESIGN, SETTING, PARTICIPANT: A randomized, double-blind, parallel-controlled, single-centered trial was conducted at Susong County People’s Hospital from October 2019 to November 2020....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaohua, Liu, Xinguo, Ye, Qiongxiang, Wang, Xunbao, Chen, Jinjun, Wang, Zhiyong, Zhao, Pengfei, Tao, Baozhou, Xu, Guoping, Xu, Wanfeng, Wu, Kan, Xiao, Yao, Yang, Li, Tian, Junqiang, Wang, Juan, Dong, Zhilong, Wang, Zhiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643168/
https://www.ncbi.nlm.nih.gov/pubmed/34876848
http://dx.doi.org/10.2147/JPR.S339006
_version_ 1784609825679736832
author Zhang, Xiaohua
Liu, Xinguo
Ye, Qiongxiang
Wang, Xunbao
Chen, Jinjun
Wang, Zhiyong
Zhao, Pengfei
Tao, Baozhou
Xu, Guoping
Xu, Wanfeng
Wu, Kan
Xiao, Yao
Yang, Li
Tian, Junqiang
Wang, Juan
Dong, Zhilong
Wang, Zhiping
author_facet Zhang, Xiaohua
Liu, Xinguo
Ye, Qiongxiang
Wang, Xunbao
Chen, Jinjun
Wang, Zhiyong
Zhao, Pengfei
Tao, Baozhou
Xu, Guoping
Xu, Wanfeng
Wu, Kan
Xiao, Yao
Yang, Li
Tian, Junqiang
Wang, Juan
Dong, Zhilong
Wang, Zhiping
author_sort Zhang, Xiaohua
collection PubMed
description OBJECTIVE: To compare the analgesic efficacy and safety of acupuncture and lornoxicam in acute renal colic (ARC). DESIGN, SETTING, PARTICIPANT: A randomized, double-blind, parallel-controlled, single-centered trial was conducted at Susong County People’s Hospital from October 2019 to November 2020. Eighty-four patients with ARC were randomly divided into lornoxicam group (Group L) and acupuncture group (Group A). Group A was treated with acupuncture at Sanyinjiao (SP6), Yinlingquan (SP9) and normal saline, and Group L was treated with sham acupuncture at SP6, SP9 and lornoxicam. MAIN OUTCOME MEASURES: Visual analogue scale (VAS) scores and adverse reactions such as nausea and dizziness were recorded within 5, 10, 15, 20 and 40 minutes after treatment. The main outcome of this study was the short-term effective (STE) rate, the secondary outcome was the onset time, and the safety index was incidence of adverse reactions. RESULTS: A total of 80 patients completed this study, including 41 patients (21 males and 20 females) in Group L and 39 patients (21 males and 18 females) in Group A. Group A exhibited lower scores versus group L after treatment (P < 0.05). The overall STE of group L was 61.00% (25/41), significantly lower than group A [84.62% (33/39)] (P < 0.001). There was no difference in the incidence of adverse reactions between group A [2.6% (1/39)] and group L [7.3% (3/41)] (P = 0.616). The ordered logistic regression analysis showed patients receiving acupuncture therapy are more likely to be cured [OR = 2.887, 95% CI: (1.190, 7.000), P = 0.019]. CONCLUSION: Acupuncture at SP6, SP9 and intramuscular injection of lornoxicam can effectively and safely relieve ARC, but the former has faster and better analgesic effect. Moreover, the incidence of adverse reactions was similar between the two treatments. This acupuncture therapy is recommended as a complementary therapy for ARC.
format Online
Article
Text
id pubmed-8643168
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86431682021-12-06 Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial Zhang, Xiaohua Liu, Xinguo Ye, Qiongxiang Wang, Xunbao Chen, Jinjun Wang, Zhiyong Zhao, Pengfei Tao, Baozhou Xu, Guoping Xu, Wanfeng Wu, Kan Xiao, Yao Yang, Li Tian, Junqiang Wang, Juan Dong, Zhilong Wang, Zhiping J Pain Res Clinical Trial Report OBJECTIVE: To compare the analgesic efficacy and safety of acupuncture and lornoxicam in acute renal colic (ARC). DESIGN, SETTING, PARTICIPANT: A randomized, double-blind, parallel-controlled, single-centered trial was conducted at Susong County People’s Hospital from October 2019 to November 2020. Eighty-four patients with ARC were randomly divided into lornoxicam group (Group L) and acupuncture group (Group A). Group A was treated with acupuncture at Sanyinjiao (SP6), Yinlingquan (SP9) and normal saline, and Group L was treated with sham acupuncture at SP6, SP9 and lornoxicam. MAIN OUTCOME MEASURES: Visual analogue scale (VAS) scores and adverse reactions such as nausea and dizziness were recorded within 5, 10, 15, 20 and 40 minutes after treatment. The main outcome of this study was the short-term effective (STE) rate, the secondary outcome was the onset time, and the safety index was incidence of adverse reactions. RESULTS: A total of 80 patients completed this study, including 41 patients (21 males and 20 females) in Group L and 39 patients (21 males and 18 females) in Group A. Group A exhibited lower scores versus group L after treatment (P < 0.05). The overall STE of group L was 61.00% (25/41), significantly lower than group A [84.62% (33/39)] (P < 0.001). There was no difference in the incidence of adverse reactions between group A [2.6% (1/39)] and group L [7.3% (3/41)] (P = 0.616). The ordered logistic regression analysis showed patients receiving acupuncture therapy are more likely to be cured [OR = 2.887, 95% CI: (1.190, 7.000), P = 0.019]. CONCLUSION: Acupuncture at SP6, SP9 and intramuscular injection of lornoxicam can effectively and safely relieve ARC, but the former has faster and better analgesic effect. Moreover, the incidence of adverse reactions was similar between the two treatments. This acupuncture therapy is recommended as a complementary therapy for ARC. Dove 2021-11-30 /pmc/articles/PMC8643168/ /pubmed/34876848 http://dx.doi.org/10.2147/JPR.S339006 Text en © 2021 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Zhang, Xiaohua
Liu, Xinguo
Ye, Qiongxiang
Wang, Xunbao
Chen, Jinjun
Wang, Zhiyong
Zhao, Pengfei
Tao, Baozhou
Xu, Guoping
Xu, Wanfeng
Wu, Kan
Xiao, Yao
Yang, Li
Tian, Junqiang
Wang, Juan
Dong, Zhilong
Wang, Zhiping
Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial
title Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial
title_full Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial
title_fullStr Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial
title_full_unstemmed Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial
title_short Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial
title_sort acupuncture versus lornoxicam in the treatment of acute renal colic: a randomized controlled trial
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643168/
https://www.ncbi.nlm.nih.gov/pubmed/34876848
http://dx.doi.org/10.2147/JPR.S339006
work_keys_str_mv AT zhangxiaohua acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT liuxinguo acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT yeqiongxiang acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT wangxunbao acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT chenjinjun acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT wangzhiyong acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT zhaopengfei acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT taobaozhou acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT xuguoping acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT xuwanfeng acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT wukan acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT xiaoyao acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT yangli acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT tianjunqiang acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT wangjuan acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT dongzhilong acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial
AT wangzhiping acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial